drugset
drugset / Trial / NCT03947528

Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions

NCT03947528 ↗

Phase 1 Unknown 38 enrolled Daewoong Pharmaceutical Co. LTD.
RandomizedCrossoverOpen-labelTreatment

Summary

A Single-dose, Comparative Bioavailability Study of Two Formulations of Sarpogrelate HCl 300mg Tablets Under Fed Conditions

Timeline

Start
2019-03-04
Primary completion
2019-05-13
Completion
2019-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Sarpogrelate Small molecule 300 mg Oral

Indications

No indication recorded.